CytoDyn Inc (OTCPK:CYDY)
$ 0.1351 -0.00065 (-0.48%) Market Cap: 143.01 Mil Enterprise Value: 172.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 32/100

Cytodyn Inc Shares Manuscript Of Potential Coronavirus Treatment Transcript

May 07, 2020 / NTS GMT
Release Date Price: $3.07 (-5.01%)
Christine Corrado
Proactive - Moderator

Hello, and welcome back to Proactive New York. I'm Christine Corrado. With me right now is Nader Pourhassan, CEO at CytoDyn; and Dr. Bruce Patterson, Diagnostic Advisor to CytoDyn. Great to see you both. How are you?

Nader Pourhassan
CytoDyn Inc. - President & CEO

Great, thank you for having us.

Questions & Answers

Christine Corrado
Proactive - Moderator

Dr. Patterson, I'll start with you first. The company is sharing an online manuscript regards to its potential coronavirus treatment. Can you tell me a bit about what this describes?

Bruce Patterson
CytoDyn Inc. - Diagnostic Advisor

This is an extremely exciting finding on COVID in general and what really makes COVID so deadly potentially, and that is the enormous amounts of this one protein called RANTES, which is not been written about in the context of COVID. RANTES is a protein, that's 100 times normal in severe COVID patients and five times normal even in mild to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot